The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

被引：0
|
作者：
Yu, Guopan [1 ]
Yao, Zurong [1 ]
Yin, Zhao [1 ]
Zhang, Yu [1 ]
Zhao, Weihua [2 ]
Weng, Guangyang [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Shi, Pengcheng [1 ]
Jiang, Xuejie [6 ]
Xu, Dan [1 ]
Xuan, Li [1 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China
[3] Shenzhen Second Peoples Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 2, Dept Hematol, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
homoharringtonine; venetoclax/azacitidine; acute myeloid leukemia; efficacy; safety;
D O I：
10.1182/blood-2024-206872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4283 / 4283
页数：1
相关论文
共 50 条
  • [1] Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study
    Yu, Guopan
    Zhang, Yu
    Jin, Hua
    Yin, Zhao
    Weng, Guangyang
    Yu, Sijian
    Xu, Na
    Du, Xin
    Lin, Dongjun
    Xiao, Jie
    Sun, Zhiqiang
    Zhang, Hongyu
    Liang, Xinquan
    Guo, Ziwen
    Zhao, Weihua
    Dai, Min
    Jiang, Xuejie
    Xuan, Li
    Shi, Pengcheng
    BLOOD, 2023, 142
  • [2] Azacitidine Plus Venetoclax for the Treatment of Relapsed and Newly Diagnosed Acute Myeloid Leukemia Patients
    Garciaz, Sylvain
    Hospital, Marie-Anne
    Alary, Anne-Sophie
    Saillard, Colombe
    Hicheri, Yosr
    Mohty, Bilal
    Rey, Jerome
    D'Incan, Evelyne
    Charbonnier, Aude
    Villetard, Ferdinand
    Maisano, Valerio
    Lombardi, Laura
    Ittel, Antoine
    Mozziconacci, Marie-Joelle
    Gelsi-Boyer, Veronique
    Vey, Norbert
    CANCERS, 2022, 14 (08)
  • [3] Azacitidine and venetoclax with or without pevonedistat in patients with newly diagnosed acute myeloid leukemia
    Short, Nicholas J.
    Wierzbowska, Agnieszka
    Cluzeau, Thomas
    Laribi, Kamel
    Recher, Christian
    Czyz, Jaroslaw
    Ochrem, Bogdan
    Ades, Lionel
    Gallego-Hernanz, Maria Pilar
    Heiblig, Mael
    Audisio, Ernesta
    Zarzycka, Ewa
    Li, Shuli
    Ferenc, Nicholas
    Yeh, Tammie
    Faller, Douglas V.
    Sedarati, Farhad
    Papayannidis, Cristina
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 458 - 468
  • [4] A Systematic Review of Venetoclax and Azacitidine: Effectiveness and Safety for Newly Diagnosed and Relapsed Acute Myeloid Leukemia Patients
    Ibrahim, Ahmed
    Yousaf, Muhammad Abdullah
    Anwar, Zain
    Anum
    Batool, Maha
    Rehman, Mohammad
    Safdar, Omar A.
    Khattak, Zeeshan Ahmed
    Faraz, Fatima
    Khalid, Huma
    BLOOD, 2023, 142
  • [5] Safety and Efficacy of Azacitidine with Venetoclax for Newly Diagnosed Intensive Chemotherapy Ineligible, and Relapsed or Refractory Acute Myeloid Leukemia in Arab Population: A Single-Center, Retrospective Study
    Alwadi, Mohammmad
    Howaidi, Jude
    Alrajhi, Abdullah M.
    Alnakhli, Adel
    Marei, Mohammed A.
    Tailor, Imran K.
    Alnajjar, Fouad H.
    Altaf, Syed Y.
    Alnoamani, Mohammed S.
    Alzahrani, Kamal
    Alshehri, Hassan
    Motabi, Ibraheem H.
    Zaidi, Syed Ziauddin A.
    Alshehry, Nawal F.
    Alfayez, Mansour
    BLOOD, 2021, 138
  • [6] Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    Chen, Hongli
    Yang, Ruoyu
    Gao, Gongzhizi
    He, Aili
    Wang, Fangxia
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2025, 16
  • [7] Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
    Cherry, Evan M.
    Abbott, Diana
    Amaya, Maria
    McMahon, Christine
    Schwartz, Marc
    Rosser, Julie
    Sato, Audrey
    Schowinsky, Jeffrey
    Inguva, Anagha
    Minhajuddin, Mohd
    Pei, Shanshan
    Stevens, Brett
    Winters, Amanda
    Jordan, Craig T.
    Smith, Clayton
    Gutman, Jonathan A.
    Pollyea, Daniel A.
    BLOOD ADVANCES, 2021, 5 (24) : 5565 - 5573
  • [8] Homoharringtonine Combining with Azacitidine and Venetoclax (HAV) As First-Line Induction Therapy for Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Lu, Wenyi
    Chen, Xiangli
    Zang, Yuzhu
    Zhu, Zunmin
    Zhang, Wenhui
    Hai, Yanliang
    Chen, Yuqing
    Jiang, Li
    Xing, Yanyan
    Liu, Yuanbo
    Shi, Jie
    Gao, Zhenxing
    BLOOD, 2024, 144 : 6037 - 6037
  • [9] Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost-Utility Analysis
    Guinan, Kimberly
    Mathurin, Karine
    Au, Yunghan
    Schuh, Andre C.
    Bui, Cat N.
    Chai, Xinglei
    Lachaine, Jean
    CURRENT ONCOLOGY, 2022, 29 (10) : 7524 - 7536
  • [10] Venetoclax Combining with Homoharringtonine,Daunorubicin and Cytarabine (HAD) As Induction Treatment in Newly Diagnosed Adult Acute Myeloid Leukemia Patients
    Yan, Zhangsong
    Li, Yang
    Zhang, Bin
    He, Jinsong
    Li, Jiesi
    Wei, Shuning
    Wang, Qi
    Li, Qiuling
    Hu, Bo
    Liu, Kaiqi
    Mi, Yingchang
    BLOOD, 2023, 142
12345